SARS-CoV-2 Antibody avidity responses in COVID-19 patients and convalescent plasma donors

87Citations
Citations of this article
129Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Convalescent plasma therapy is a leading treatment for conferring temporary immunity to COVID-19-susceptible individuals or for use as post-exposure prophylaxis. However, not all recovered patients develop adequate antibody titers for donation and the relationship between avidity and neutralizing titers is currently not well understood. Methods: SARS-CoV-2 anti-spike and anti-nucleocapsid IgG titers and avidity were measured in a longitudinal cohort of COVID-19 hospitalized patients (n= 16 individuals) and a cross-sectional sample of convalescent plasma donors (n =130). Epidemiologic correlates of avidity were examined in donors by linear regression. The association of avidity and a high neutralizing titer (NT) were also assessed in donors using modified Poisson regression. Results: Antibody avidity increased over duration of infection and remained elevated. In convalescent plasma donors, higher levels of anti-spike avidity were associated with older age, male sex, and hospitalization. Higher NTs had a stronger positive correlation with anti-spike IgG avidity (Spearman ρ = 0.386; P

Cite

CITATION STYLE

APA

Benner, S. E., Patel, E. U., Laeyendecker, O., Pekosz, A., Littlefield, K., Eby, Y., … Redd, A. D. (2020). SARS-CoV-2 Antibody avidity responses in COVID-19 patients and convalescent plasma donors. Journal of Infectious Diseases, 222(12), 1974–1984. https://doi.org/10.1093/infdis/jiaa581

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free